Sara Nochur is an independent member of the board of City Therapeutics.

Dr. Nochur has 35 years of drug development and industry leadership experience with a focus on regulatory affairs. Most recently, she served as Chief Diversity, Equity and Inclusion Officer at Alnylam Pharmaceuticals. Prior to that, Dr. Nochur was Alnylam’s Chief Regulatory Officer. In that role, she built a large international regulatory affairs team. She led the development and global approval of four novel RNAi therapeutics, including ONPATTRO®, GIVLAARI®, OXLUMO®, and LEQVIO®.

Prior to her 18 years at Alnylam, Dr. Nochur held leadership roles in regulatory affairs at The Medicines Company, Ceremedix, and BioTrack, and in new product development and diagnostics with DynaGen. She is a prior board director of Marinus Pharmaceuticals and Decibel Therapeutics. Currently, Dr. Nochur sits on the board of the Biomedical Science Careers Program, a non-profit that increases representation of underrepresented minority and disadvantaged individuals in science and medicine, and Hospitality Homes, which provides free or low-cost housing for patients and caregivers receiving specialty medical care in Boston-area hospitals.

Dr. Nochur holds a Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and an M.S. in Microbiology and a B.S. in Microbiology and Chemistry from the University of Bombay.